KR20190061737A - Composition for Preventing, Improving or Treating Sleep Disorder Comprising Passiflora caerulea extract as an Active Ingredients - Google Patents
Composition for Preventing, Improving or Treating Sleep Disorder Comprising Passiflora caerulea extract as an Active Ingredients Download PDFInfo
- Publication number
- KR20190061737A KR20190061737A KR1020170160414A KR20170160414A KR20190061737A KR 20190061737 A KR20190061737 A KR 20190061737A KR 1020170160414 A KR1020170160414 A KR 1020170160414A KR 20170160414 A KR20170160414 A KR 20170160414A KR 20190061737 A KR20190061737 A KR 20190061737A
- Authority
- KR
- South Korea
- Prior art keywords
- extract
- present
- preventing
- clock flower
- composition
- Prior art date
Links
- 239000000284 extract Substances 0.000 title claims abstract description 76
- 239000000203 mixture Substances 0.000 title claims abstract description 28
- 208000019116 sleep disease Diseases 0.000 title claims abstract description 27
- 244000136041 Passiflora caerulea Species 0.000 title claims abstract description 10
- 235000011918 Passiflora caerulea Nutrition 0.000 title claims abstract description 10
- 208000020685 sleep-wake disease Diseases 0.000 title claims description 16
- 239000004480 active ingredient Substances 0.000 title claims description 11
- 230000000971 hippocampal effect Effects 0.000 claims abstract description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 22
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 20
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 15
- 239000008194 pharmaceutical composition Substances 0.000 claims description 15
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 14
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 11
- 102000004169 proteins and genes Human genes 0.000 claims description 10
- 108090000623 proteins and genes Proteins 0.000 claims description 10
- 210000003016 hypothalamus Anatomy 0.000 claims description 8
- 235000013376 functional food Nutrition 0.000 claims description 6
- 239000002904 solvent Substances 0.000 claims description 6
- 230000036541 health Effects 0.000 claims description 5
- 235000013399 edible fruits Nutrition 0.000 claims description 4
- 230000002267 hypothalamic effect Effects 0.000 claims description 4
- 101710132601 Capsid protein Proteins 0.000 claims 1
- 102000007568 Proto-Oncogene Proteins c-fos Human genes 0.000 abstract description 17
- 108010071563 Proto-Oncogene Proteins c-fos Proteins 0.000 abstract description 17
- 210000001320 hippocampus Anatomy 0.000 abstract description 11
- 230000008929 regeneration Effects 0.000 abstract description 8
- 238000011069 regeneration method Methods 0.000 abstract description 8
- 210000000691 mamillary body Anatomy 0.000 abstract description 7
- 210000005036 nerve Anatomy 0.000 abstract description 7
- 230000001965 increasing effect Effects 0.000 description 16
- 230000000694 effects Effects 0.000 description 15
- 210000001519 tissue Anatomy 0.000 description 14
- 101000720704 Homo sapiens Neuronal migration protein doublecortin Proteins 0.000 description 11
- 102100025929 Neuronal migration protein doublecortin Human genes 0.000 description 11
- 210000005013 brain tissue Anatomy 0.000 description 10
- 241000699666 Mus <mouse, genus> Species 0.000 description 9
- 230000007958 sleep Effects 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 8
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 8
- 208000035475 disorder Diseases 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 235000018102 proteins Nutrition 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- 239000000796 flavoring agent Substances 0.000 description 6
- 235000013305 food Nutrition 0.000 description 6
- 235000013355 food flavoring agent Nutrition 0.000 description 6
- 230000006872 improvement Effects 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 150000001720 carbohydrates Chemical class 0.000 description 5
- 235000014633 carbohydrates Nutrition 0.000 description 5
- 210000002569 neuron Anatomy 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 238000012790 confirmation Methods 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 208000019901 Anxiety disease Diseases 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 229930091371 Fructose Natural products 0.000 description 3
- 239000005715 Fructose Substances 0.000 description 3
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 3
- 102000027484 GABAA receptors Human genes 0.000 description 3
- 108091008681 GABAA receptors Proteins 0.000 description 3
- 208000032612 Glial tumor Diseases 0.000 description 3
- 206010018338 Glioma Diseases 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 230000036506 anxiety Effects 0.000 description 3
- 229940049706 benzodiazepine Drugs 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 210000003238 esophagus Anatomy 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 238000003364 immunohistochemistry Methods 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 3
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 235000010356 sorbitol Nutrition 0.000 description 3
- 229960002920 sorbitol Drugs 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 2
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
- 108010011485 Aspartame Proteins 0.000 description 2
- 206010010904 Convulsion Diseases 0.000 description 2
- 241000186249 Corynebacterium sp. Species 0.000 description 2
- 229920000858 Cyclodextrin Polymers 0.000 description 2
- RGSFGYAAUTVSQA-UHFFFAOYSA-N Cyclopentane Chemical compound C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- 239000004386 Erythritol Substances 0.000 description 2
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 2
- AMQJEAYHLZJPGS-UHFFFAOYSA-N N-Pentanol Chemical compound CCCCCO AMQJEAYHLZJPGS-UHFFFAOYSA-N 0.000 description 2
- 241000218996 Passiflora Species 0.000 description 2
- 206010039897 Sedation Diseases 0.000 description 2
- 244000228451 Stevia rebaudiana Species 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000000605 aspartame Substances 0.000 description 2
- 235000010357 aspartame Nutrition 0.000 description 2
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 2
- 229960003438 aspartame Drugs 0.000 description 2
- 150000001557 benzodiazepines Chemical class 0.000 description 2
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 2
- -1 chlorine ions Chemical class 0.000 description 2
- MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 description 2
- DIOQZVSQGTUSAI-UHFFFAOYSA-N decane Chemical compound CCCCCCCCCC DIOQZVSQGTUSAI-UHFFFAOYSA-N 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- LJSQFQKUNVCTIA-UHFFFAOYSA-N diethyl sulfide Chemical compound CCSCC LJSQFQKUNVCTIA-UHFFFAOYSA-N 0.000 description 2
- 150000002016 disaccharides Chemical class 0.000 description 2
- 235000019414 erythritol Nutrition 0.000 description 2
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 2
- 229940009714 erythritol Drugs 0.000 description 2
- 239000003925 fat Substances 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 235000013402 health food Nutrition 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- 150000002772 monosaccharides Chemical class 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 239000012454 non-polar solvent Substances 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 229920001542 oligosaccharide Polymers 0.000 description 2
- 150000002482 oligosaccharides Chemical class 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000002798 polar solvent Substances 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 2
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 2
- 230000036280 sedation Effects 0.000 description 2
- 208000022925 sleep disturbance Diseases 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 150000005846 sugar alcohols Chemical class 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- GRWFGVWFFZKLTI-UHFFFAOYSA-N α-pinene Chemical compound CC1=CCC2C(C)(C)C1C2 GRWFGVWFFZKLTI-UHFFFAOYSA-N 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
- VFWCMGCRMGJXDK-UHFFFAOYSA-N 1-chlorobutane Chemical compound CCCCCl VFWCMGCRMGJXDK-UHFFFAOYSA-N 0.000 description 1
- SQCZQTSHSZLZIQ-UHFFFAOYSA-N 1-chloropentane Chemical compound CCCCCCl SQCZQTSHSZLZIQ-UHFFFAOYSA-N 0.000 description 1
- GRWFGVWFFZKLTI-IUCAKERBSA-N 1S,5S-(-)-alpha-Pinene Natural products CC1=CC[C@@H]2C(C)(C)[C@H]1C2 GRWFGVWFFZKLTI-IUCAKERBSA-N 0.000 description 1
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 1
- FXNDIJDIPNCZQJ-UHFFFAOYSA-N 2,4,4-trimethylpent-1-ene Chemical group CC(=C)CC(C)(C)C FXNDIJDIPNCZQJ-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 229930000680 A04AD01 - Scopolamine Natural products 0.000 description 1
- 206010000372 Accident at work Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 241001474374 Blennius Species 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- 239000001512 FEMA 4601 Substances 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 1
- 206010021118 Hypotonia Diseases 0.000 description 1
- 102000004310 Ion Channels Human genes 0.000 description 1
- NHTMVDHEPJAVLT-UHFFFAOYSA-N Isooctane Chemical compound CC(C)CC(C)(C)C NHTMVDHEPJAVLT-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 238000012347 Morris Water Maze Methods 0.000 description 1
- 240000000249 Morus alba Species 0.000 description 1
- 235000008708 Morus alba Nutrition 0.000 description 1
- 101100309526 Mus musculus Sat1 gene Proteins 0.000 description 1
- 206010049816 Muscle tightness Diseases 0.000 description 1
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 1
- 240000002853 Nelumbo nucifera Species 0.000 description 1
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical group CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 241000237502 Ostreidae Species 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 241000554910 Pulsatilla cernua var. koreana Species 0.000 description 1
- HELXLJCILKEWJH-SEAGSNCFSA-N Rebaudioside A Natural products O=C(O[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]1(C)[C@@H]2[C@](C)([C@H]3[C@@]4(CC(=C)[C@@](O[C@H]5[C@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@H](O)[C@@H](CO)O5)(C4)CC3)CC2)CCC1 HELXLJCILKEWJH-SEAGSNCFSA-N 0.000 description 1
- 206010039203 Road traffic accident Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- 244000126002 Ziziphus vulgaris Species 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000012675 alcoholic extract Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- MVNCAPSFBDBCGF-UHFFFAOYSA-N alpha-pinene Natural products CC1=CCC23C1CC2C3(C)C MVNCAPSFBDBCGF-UHFFFAOYSA-N 0.000 description 1
- 229940082988 antihypertensives serotonin antagonists Drugs 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000003420 antiserotonin agent Substances 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000005978 brain dysfunction Effects 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 210000003792 cranial nerve Anatomy 0.000 description 1
- KTHXBEHDVMTNOH-UHFFFAOYSA-N cyclobutanol Chemical compound OC1CCC1 KTHXBEHDVMTNOH-UHFFFAOYSA-N 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000004970 emotional disturbance Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- HELXLJCILKEWJH-UHFFFAOYSA-N entered according to Sigma 01432 Natural products C1CC2C3(C)CCCC(C)(C(=O)OC4C(C(O)C(O)C(CO)O4)O)C3CCC2(C2)CC(=C)C21OC(C1OC2C(C(O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1O HELXLJCILKEWJH-UHFFFAOYSA-N 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- DMEGYFMYUHOHGS-UHFFFAOYSA-N heptamethylene Natural products C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000004941 influx Effects 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 229960004592 isopropanol Drugs 0.000 description 1
- ULYZAYCEDJDHCC-UHFFFAOYSA-N isopropyl chloride Chemical compound CC(C)Cl ULYZAYCEDJDHCC-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 201000003723 learning disability Diseases 0.000 description 1
- 229940069445 licorice extract Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 230000007787 long-term memory Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 210000005171 mammalian brain Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000005056 memory consolidation Effects 0.000 description 1
- 230000006984 memory degeneration Effects 0.000 description 1
- 206010027175 memory impairment Diseases 0.000 description 1
- 208000023060 memory loss Diseases 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 230000036640 muscle relaxation Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- SNMVRZFUUCLYTO-UHFFFAOYSA-N n-propyl chloride Chemical compound CCCCl SNMVRZFUUCLYTO-UHFFFAOYSA-N 0.000 description 1
- 239000003345 natural gas Substances 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 230000017511 neuron migration Effects 0.000 description 1
- 210000002445 nipple Anatomy 0.000 description 1
- 231100000989 no adverse effect Toxicity 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000020636 oyster Nutrition 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 235000019203 rebaudioside A Nutrition 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 1
- 229960002646 scopolamine Drugs 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000006403 short-term memory Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000007596 spatial working memory Effects 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229940125725 tranquilizer Drugs 0.000 description 1
- 239000003204 tranquilizing agent Substances 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 238000005292 vacuum distillation Methods 0.000 description 1
- 238000009777 vacuum freeze-drying Methods 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/31—Foods, ingredients or supplements having a functional effect on health having an effect on comfort perception and well-being
-
- Y10S514/923—
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Botany (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medical Informatics (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Description
본 발명은 시계꽃 추출물을 유효성분으로 포함하는 수면장애의 예방, 개선 또는 치료용 조성물에 관한 것이다.The present invention relates to a composition for preventing, ameliorating or treating a sleep disorder, which comprises a clock flower extract as an active ingredient.
수면장애는 현대인들이 흔히 겪는 문제 중의 하나로, 수면장애란 건강한 수면을 취하지 못하거나, 충분한 수면을 취하고 있음에도 낮 동안에 각성을 유지하지 못하는 상태, 또는 수면리듬이 흐트러져 있어서 잠자거나 깨어 있을 때 어려움을 겪는 상태를 의미하는 것이다. Sleep disturbance is one of the common problems that modern people are experiencing. Sleep disorder is a condition that does not take a healthy sleep, does not maintain awakening during the day despite having sufficient sleep, or is in trouble when sleeping or awake due to disordered sleep rhythm. It means.
이와 같이 수면장애는 정신적인 문제가 큰 원인이 되기도 하는데 과도한 스트레스와 불안감, 긴장감, 공포 등으로 인해 발생할 수 있는 것으로 알려져 있다. 수면장애는 인구의 약 20% 이상이 경험한 적이 있거나 앓고 있는 상당히 흔한 질환으로, 여러 가지 개인적, 사회적 문제를 초래할 수 있으며 학습장애, 능률저하, 교통사고, 안전사고, 정서장애, 사회 적응장애, 결혼생활의 불만족, 산업재해 등의 원인이 될 수 있다. 또한 수면장애를 적절하게 치료하지 않으면 이미 앓고 있는 내과적, 신경과적, 정신과적 질환이 악화되거나 회복이 지연될 수 있고 심근경색증, 뇌졸중 등의 심각한 병을 초래하기도 한다. 이에 수면보조제에 대한 관심이 높아지고 있다.As such, sleep disorder is a major cause of mental problems, but it can be caused by excessive stress, anxiety, tension, and fear. Sleep disorder is a fairly common disease that has been or has been experienced by more than 20% of the population and can lead to a variety of personal and social problems, including learning disabilities, inefficiencies, traffic accidents, safety accidents, emotional disturbances, Dissatisfaction with marriage, and industrial accidents. In addition, if the sleep disorder is not properly treated, the medical, neurological and psychiatric illnesses already suffering may be worsened or the recovery may be delayed, and serious diseases such as myocardial infarction and stroke may be caused. There is a growing interest in sleep aids.
상기 수면장애의 치료 약물로는 주로 벤조다이아제핀 계열의 약물과 세로토닌 효능약 등이 사용되고 있다. 벤조다이아제핀을 포함하여 많은 약물들이 GABAA 수용체에 결합하여 약리작용을 수행하고 있고, 벤조다이아제핀 부위에 약물 또는 보조제가 결합하면 GABA에 대한 GABAA 수용체 친화도를 증진시키며, 염소 이온의 세포 내 유입을 증가시켜 불안 완화, 경련 개선, 진정 작용, 및 수면 유도 및 개선 효과를 보인다. GABAA 수용체는 멤브레인 이온 채널을 형성하는 펜타머릭 단백질로서, 진정, 수면, 불안, 근육긴장, 경련, 기억 상실 등의 조절과 밀접한 관련이 있으며, 이를 통하여 GABA(감마-아미노부티르산)이 작용하게 된다. 이러한 약물들은 장기간 사용하였을 때 내성 및 의존성이 형성되는 부작용을 동반하며 근육완화 및 건망증 등의 심각한 문제를 초래하기도 한다.Benzodiazepines and serotonin antagonists have been used as therapeutic agents for sleep disorders. Many drugs, including benzodiazepines, bind to GABAA receptors and perform pharmacological actions. When a drug or adjuvant is bound to the benzodiazepine site, the GABAA receptor affinity for GABA is enhanced, and the intracellular influx of chlorine ions To improve anxiety, to improve seizure, to sedation, and to induce and improve sleep. The GABAA receptor is a pentameric protein that forms a membrane ion channel and is closely related to the regulation of sedation, sleep, anxiety, muscle tension, convulsions, memory loss, etc. through which GABA (gamma-aminobutyric acid) acts. These drugs, when used for a long period of time, are accompanied by side effects that result in resistance and dependence, and may cause serious problems such as muscle relaxation and forgetfulness.
따라서, 수면제 장기 복용자 및 제한자의 경우 이를 대체할 수 있는 수단으로 천연 보조제의 필요성이 높아지고 있으며, 수면 증진 건강기능식품에 대한 수요가 증대되고 있다.Therefore, the need for natural supplements is increasing as a means of replacing sleeping pills in the case of long-term sleepers and restrictors, and the demand for functional foods for sleep enhancement is increasing.
이와 관련하여 대한민국 등록특허 제10-0947353호는 수면장애 개선과 쾌면을 위한 건강식품 조성물을 제공하고 있으며, 특히 천연물 중에서 쾌면에 도움을 준다고 알려진 산조인, 토란대, 연자육, 연근과 마그네슘으로 구성된 환으로 멜라토닌 함량을 높여 우수한 수면장애 개선 효능을 나타내는 수면 장애 개선과 쾌면을 위한 건강식품 조성물에 관하여 개시하고 있다.In this regard, Korean Patent No. 10-0947353 provides a health food composition for improvement of sleeping disorder and a pleasant surface. Especially, it is a ring composed of a sanjoin, a tranquilizer, a livestock meat, a lotus root and magnesium, Discloses a health food composition for improvement of sleeping disorder and a pleasant surface that exhibits excellent sleeping disorder improving effect by increasing the content.
또한 대한민국 공개특허공보 제10-2014-0030454호에서는 굴과 해조류의 혼합물을 발효시켜 천연 가바를 함유하는 스트레스 해소 또는 수면장애 개선용 발효소재 및 이의 제조방법을 제공하며, 굴과 해조류의 혼합물을 발효시켜 다량의 천연 GABA를 함유하는 스트레스 해소 또는 수면장애 개선용 발효소재 및 이의 제조방법을 제공한다. Korean Patent Laid-Open Publication No. 10-2014-0030454 also discloses a fermentation material for relieving stress or improving sleeping disturbance containing a natural gas and fermenting a mixture of oysters and seaweeds, and a method for producing the same, Which contains a large amount of natural GABA, and a method for producing the fermented material.
본 발명자들은 수면장애를 예방 또는 치료할 수 있는 천연물을 개발하고자 노력하였다. 그 결과, 본 발명자들은 시계꽃(Passiflora caerulea ) 추출물이 유두체 및 해마 조직에서 씨포스(c-fos) 발현량을 증가시키고, 해마에서 DCX 단백질의 발현을 증가시키며, 뇌조직에서의 신경재생을 촉진함으로써, 수면장애 치료 및 개선 효과를 가진다는 것을 확인함으로써, 본 발명을 완성하였다.The present inventors have sought to develop natural products capable of preventing or treating sleep disorders. As a result, the present inventors have found that clock flower (Passiflora caerulea) extracts the seed Force (c-fos) increase the expression level, increase the expression of the DCX protein in the hippocampus, by promoting nerve regeneration in brain tissue, sleep disorder, and improvement in the nipple body and the hippocampus tissue The present invention has been completed.
따라서, 본 발명의 목적은 수면장애의 예방, 개선 또는 치료용 조성물을 제공하는 데 있다.Accordingly, it is an object of the present invention to provide a composition for preventing, ameliorating or treating sleep disorders.
그러나 본 발명이 이루고자 하는 기술적 과제는 이상에서 언급한 과제에 제한되지 않으며, 언급되지 않은 또 다른 과제들은 아래의 기재로부터 당업자에게 명확하게 이해될 수 있을 것이다.However, the technical problem to be solved by the present invention is not limited to the above-mentioned problems, and other matters not mentioned can be clearly understood by those skilled in the art from the following description.
상기 목적을 달성하기 위해서, 본 발명은 시계꽃(Passiflora caerulea) 추출물을 유효성분으로 포함하는, 수면장애의 예방, 개선, 또는 치료용 약학적 조성물을 제공한다.In order to achieve the above object, the present invention provides clock flower (Passiflora The present invention also provides a pharmaceutical composition for preventing, ameliorating, or treating sleep disorders, which comprises an extract of Corynebacterium sp .
본 발명의 일 구현예로, 상기 추출물은 물, 에탄올, 디클로로메탄, 에틸아세테이트, 및 부탄올로 이루어지는 군으로부터 선택되는 1종의 용매로 추출된 추출물인 것을 특징으로 한다.In one embodiment of the present invention, the extract is an extract extracted with one kind of solvent selected from the group consisting of water, ethanol, dichloromethane, ethyl acetate, and butanol.
본 발명의 다른 구현예로, 상기 시계꽃 추출물은 시계꽃의 잎 또는 열매 추출물인 것을 특징으로 한다.In another embodiment of the present invention, the clock flower extract is a leaf or fruit extract of a clock flower.
본 발명의 또다른 구현예로, 상기 추출물은 해마 조직에서 씨포스(C-fos) 및 더블코르틴(Doublecortin, DCX) 단백질의 발현을 증가시키는 것을 특징으로 한다.In another embodiment of the present invention, the extract is characterized by increasing the expression of C-fos and Doublecortin (DCX) proteins in hippocampal tissue.
본 발명의 또다른 구현예로, 상기 추출물은 시상하부의 유두체 조직에서 C-fos 단백질의 발현을 증가시키는 것을 특징으로 한다.In another embodiment of the present invention, the extract is characterized in that the expression of C-fos protein is increased in the hypothalamic papillary body tissue.
또한, 본 발명은 시계꽃(Passiflora caerulea) 추출물을 유효성분으로 포함하는, 수면장애 개선용 건강기능성 식품 조성물을 제공한다.The present invention also relates to a method for producing The present invention provides a health functional food composition for improving sleeping disorder, which comprises, as an active ingredient,
본 발명은 시계꽃(Passiflora caerulea) 추출물을 통해 뇌조직에 대한 영향을 확인한 결과, 열수 추출물에 해마 조직에서 C-fos 및 DCX 단백질의 발현을 증가시키고, 시상하부의 유두체 조직에서 C-fos 단백질의 발현을 증가시키며, 신경재생 효과가 있다는 것이 확인되어, 본 발명의 시계꽃 추출물을 포함하는 조성물은 수면장애 관련 질환에 있어 우수한 치료, 예방 및 개선 효과를 보일 것으로 예상된다.The invention watch flower (Passiflora caerulea ), the expression of C-fos and DCX protein in hippocampal tissues was increased, the expression of C-fos protein was increased in the hypothalamic tissue of the hypothalamus, It is expected that the composition containing the clock flower extract of the present invention will exhibit an excellent treatment, prevention and improvement effect in sleep disorder related diseases.
도 1은 본 발명의 시계꽃 추출물이 C6 glioma cell의 intracellular ROS production와 viability에 미치는 효능을 확인한 결과를 나타낸 도면이다.
도 2는 시계꽃 추출물의 경구투여가 마우스 시상하부의 mammillary body 조직에 미치는 효과를 확인한 결과를 나타낸 도면이다.
도 3은 시계꽃 추출물 투여에 의한 랫드 해마조직에서 c-fos 단백질의 증가를 확인한 결과를 나타낸 도면이다.
도 4는 시계꽃 추출물 투여에 의한 랫드 해마조직에서 신경재생의 지표인 DCX 단백질의 증가를 확인한 결과를 나타낸 도면이다.
도 5는 water maze test를 통해 시계꽃 추출물이 DBA/2 mouse의 학습효과를 증진시킬 수 있음을 확인한 결과를 나타낸 도면이다.FIG. 1 is a graph showing the effect of the clock flower extract of the present invention on intracellular ROS production and viability of C6 glioma cells.
FIG. 2 is a diagram showing the results of confirming the effect of oral administration of a clock flower extract on the mammillary body tissue of the hypothalamus of the mouse.
FIG. 3 is a graph showing the results of confirming the increase of c-fos protein in rat hippocampus tissue by administration of clock flower extract.
FIG. 4 is a graph showing the results of confirming the increase of DCX protein, which is an index of nerve regeneration, in rat hippocampus tissue by administration of clock flower extract.
FIG. 5 is a graph showing the results of confirming that the clock flower extract can enhance the learning effect of DBA / 2 mouse through water maze test.
본 발명자들은, 수면장애를 예방 또는 치료 효과가 증진된 천연물을 개발하고자 예의 노력한 결과, 시계꽃(Passiflora caerulea) 추출물에 뇌 조직에서 신경세포의 재생 효과가 있다는 것을 확인하여 본 발명을 완성하였다.The present inventors have made intensive efforts to develop a natural product with improved sleep disorder prevention or therapeutic effect, and as a result, confirmed that the extract of Passiflora caerulea has a regenerating effect on nerve cells in brain tissue, thereby completing the present invention.
즉, 본 발명은 시계꽃(Passiflora caerulea) 추출물을 유효성분으로 포함하는, 수면장애의 예방, 개선, 또는 치료용 약학적 조성물을 제공한다.That is, the present invention provides clock flower (Passiflora The present invention also provides a pharmaceutical composition for preventing, ameliorating, or treating sleep disorders, which comprises an extract of Corynebacterium sp .
또한, 본 발명은 시계꽃(Passiflora caerulea) 추출물을 유효성분으로 포함하는, 수면장애 개선용 건강기능성 식품 조성물을 제공한다.The present invention also relates to a method for producing The present invention provides a health functional food composition for improving sleeping disorder, which comprises, as an active ingredient,
본 발명의 조성물에서 이용되는 시계꽃 추출물은, 시계꽃 전초, 잎 또는 열매에 용매를 첨가하여 추출된 추출물로, 상기 추출물은 물, 에탄올, 디클로로메탄, 에틸아세테이트, 부탄올 및 이의 혼합용매로 이루어지는 군으로부터 선택되는 1종의 용매로 추출된 것일 수 있고, 바람직하게는 물(열수) 추출물일 수 있다. The clock flower extract used in the composition of the present invention is an extract obtained by adding a solvent to a clock flower flower, a leaf or a fruit, and the extract is a mixture of water, ethanol, dichloromethane, ethyl acetate, butanol, , And preferably may be a water (hot water) extract.
상기 추출물은 시계꽃에 추출용매를 처리하여 수득하는 것으로, 다양한 추출용매가 이용될 수 있다. 본 발명의 일 구현예에 따르면, 극성 용매 또는 비극성 용매를 이용할 수 있다. 극성 용매로서 적합한 것은, (i) 물, (ii) 알코올(바람직하게는, 메탄올, 에탄올, 프로판올, 부탄올, 노말-프로판올, 이소-프로판올, 노말-부탄올, 1-펜탄올, 2-부톡시에탄올 또는 에틸렌글리콜), (iii) 아세트산, (iv) DMFO(dimethyl-formamide) 및 (v) DMSO(dimethyl sulfoxide)를 포함한다. 비극성 용매로서 적합한 것은, 아세톤, 아세토나이트릴, 에틸 아세테이트, 메틸 아세테이트, 플루오로알칸, 펜탄, 부탄올, 2,2,4-트리메틸펜탄, 데칸, 사이클로부탄올, 사이클로펜탄, 디이소부틸렌, 1-펜텐, 1-클로로부탄, 1-클로로펜탄, o-자일렌, 디이소프로필 에테르, 2-클로로프로판, 톨루엔, 1-클로로프로판, 클로로벤젠, 벤젠, 디에틸 에테르, 디에틸 설파이드, 클로로포름, 디클로로메탄, 1,2-디클로로에탄, 어닐린, 디에틸아민, 에테르, 사염화탄소 및 THF를 포함할 수 있으며, 바람직하게는 본 발명의 실시예와 같이 물 또는 에탄올을 이용할 수 있다. 본 발명에서 이용되는 시계꽃 추출물은 감압 증류 및 동결 건조 또는 분무 건조 등과 같은 추가적인 과정에 의해 분말 상태로 제조된 것을 이용할 수 있다.The extract is obtained by treating an extractive solvent in a clock flower, and various extraction solvents can be used. According to one embodiment of the present invention, a polar solvent or a non-polar solvent can be used. Suitable polar solvents are (i) water, (ii) alcohols (preferably methanol, ethanol, propanol, butanol, n-propanol, iso-propanol, n-butanol, 1-pentanol, Or ethylene glycol), (iii) acetic acid, (iv) dimethyl-formamide (DMFO) and (v) dimethyl sulfoxide (DMSO). Suitable nonpolar solvents are acetone, acetonitrile, ethyl acetate, methyl acetate, fluoroalkane, pentane, butanol, 2,2,4-trimethylpentane, decane, cyclobutanol, cyclopentane, diisobutylene, 1- But are not limited to, pentane, 1-chlorobutane, 1-chloropentane, o -xylene, diisopropyl ether, 2- chloropropane, toluene, 1- chloropropane, chlorobenzene, benzene, diethyl ether, diethylsulfide, Methane, 1,2-dichloroethane, aniline, diethylamine, ether, carbon tetrachloride, and THF. Preferably, water or ethanol may be used as in the embodiment of the present invention. The clock flower extract used in the present invention may be prepared in powder form by an additional process such as vacuum distillation, freeze drying, or spray drying.
본 명세서에서 용어 '유효성분으로 포함하는'이란 하기의 시계꽃 추출물의 효능 또는 활성을 달성하는 데 충분한 양을 포함하는 것을 의미한다. 본 발명은 천연식물재료인 시계꽃(Passiflora caerulea)로부터 추출한 추출물로서 과량 투여하여도 인체에 부작용이 없으므로 시계꽃 추출물이 본 발명의 조성물에 포함된 양적 상한은 당업자가 적절한 범위 내에서 선택하여 실시할 수 있다.As used herein, the term " comprising as an active ingredient " is meant to include an amount sufficient to achieve efficacy or activity of the timepiece flower extracts described below. The present invention is an extract extracted from a natural flower material ( Passiflora caerulea ), and there is no adverse effect on the human body even when it is administered in an excessive amount. Therefore, the quantitative upper limit in which the clock flower extract is included in the composition of the present invention is selected by a person skilled in the art .
본 발명의 조성물은 뇌신경 조직의 기능 저하와 같이 시상하부 유두체 및 해마 조직의 기능 이상과 관련된 수면장애의 예방, 개선 또는 치료하는 데 유효한 것으로, 시상하부의 유두체 및 해마 조직에서 C-fos 단백질의 발현을 증가시키고, 해마조직에서 DCX 단백질의 발현의 증가를 유도할 수 있다.The composition of the present invention is effective for preventing, ameliorating, or treating sleep disorders related to dysfunction of hypothalamus and hippocampal tissues such as brain dysfunction. The composition of C-fos protein Lt; RTI ID = 0.0 > DCX < / RTI > protein in hippocampal tissues.
본 발명의 약학적 조성물은 (a) 상술한 본 발명의 시계꽃 추출물의 약학적 유효량; 및 (b) 약학적으로 허용되는 담체를 포함하는 약학적 조성물이다. 본 명세서에서 용어 "약학적 유효량"은 상술한 시계꽃 추출물의 효능 또는 활성을 달성하는 데 충분한 양을 의미한다.The pharmaceutical composition of the present invention comprises (a) a pharmaceutically effective amount of the above-mentioned clock flower extract of the present invention; And (b) a pharmaceutically acceptable carrier. As used herein, the term " pharmaceutically effective amount " means an amount sufficient to achieve efficacy or activity of the clock flower extract described above.
본 발명의 조성물이 약학적 조성물로 제조되는 경우, 본 발명의 약학적 조성물은 약학적으로 허용되는 담체를 포함한다. 본 발명의 약학적 조성물에 포함되는 약학적으로 허용되는 담체는 제제시에 통상적으로 이용되는 것으로서, 락토스, 덱스트로스, 수크로스, 솔비톨, 만니톨, 전분, 아카시아 고무, 인산 칼슘, 알기네이트, 젤라틴, 규산 칼슘, 미세결정성 셀룰로스, 폴리비닐피롤리돈, 셀룰로스, 물, 시럽, 메틸 셀룰로스, 메틸히드록시벤조에이트, 프로필히드록시벤조에이트, 활석, 스테아르산 마그네슘 및 미네랄 오일 등을 포함하나, 이에 한정되는 것은 아니다. 본 발명의 약학적 조성물은 상기 성분들 이외에 윤활제, 습윤제, 감미제, 향미제, 유화제, 현탁제, 보존제 등을 추가로 포함할 수 있다.When the composition of the present invention is prepared from a pharmaceutical composition, the pharmaceutical composition of the present invention includes a pharmaceutically acceptable carrier. The pharmaceutically acceptable carriers to be contained in the pharmaceutical composition of the present invention are those conventionally used in the present invention and include lactose, dextrose, sucrose, sorbitol, mannitol, starch, acacia rubber, calcium phosphate, alginate, gelatin, But are not limited to, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrups, methylcellulose, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil. It is not. The pharmaceutical composition of the present invention may further contain a lubricant, a wetting agent, a sweetening agent, a flavoring agent, an emulsifying agent, a suspending agent, a preservative, etc., in addition to the above components.
본 발명의 약학적 조성물은 경구 또는 비경구 투여할 수 있다. 본 발명의 일 구현예에 따르면, 경구 투여 방식으로 적용된다.The pharmaceutical composition of the present invention can be administered orally or parenterally. According to one embodiment of the invention, it is applied in an oral administration mode.
본 발명의 약학적 조성물의 적합한 투여량은 제제화 방법, 투여 방식, 환자의 연령, 체중, 성, 병적 상태, 음식, 투여 시간, 투여 경로, 배설 속도 및 반응 감응성과 같은 요인들에 의해 다양하게 처방될 수 있다. 본 발명의 약학적 조성물의 일반적인 투여량은 성인 기준으로 0.001-100 ㎎/kg 범위 내이다.The appropriate dosage of the pharmaceutical composition of the present invention may vary depending on such factors as formulation method, administration method, age, body weight, sex, pathological condition, food, administration time, route of administration, excretion rate, . Typical dosages of the pharmaceutical compositions of the invention are in the range of 0.001-100 mg / kg on an adult basis.
본 발명의 약학적 조성물은 당해 발명이 속하는 기술분야에서 통상의 지식을 가진 자가 용이하게 실시할 수 있는 방법에 따라, 약학적으로 허용되는 담체 및/또는 부형제를 이용하여 제제화함으로써 단위 용량 형태로 제조되거나 또는 다용량 용기 내에 내입시켜 제조될 수 있다. 이때 제형은 오일 또는 수성 매질중의 용액, 현탁액, 시럽제 또는 유화액 형태이거나 엑스제, 산제, 분말제, 과립제, 정제 또는 캅셀제 형태일 수도 있으며, 분산제 또는 안정화제를 추가적으로 포함할 수 있다.The pharmaceutical composition of the present invention may be formulated into a unit dosage form by using a pharmaceutically acceptable carrier and / or excipient according to a method which can be easily carried out by those having ordinary skill in the art to which the present invention belongs. Or by intrusion into a multi-dose container. The formulations may be in the form of solutions, suspensions, syrups or emulsions in oils or aqueous media, or in the form of excipients, powders, powders, granules, tablets or capsules, and may additionally contain dispersing or stabilizing agents.
본 발명의 조성물은 식품 조성물로 제공될 수 있다. 본 발명의 시계꽃 추출물을 유효성분으로 포함하는 수면장애의 예방, 개선 또는 치료용 조성물이 식품 조성물로 제조되는 경우, 유효성분으로서 시계꽃 추출물뿐 만 아니라, 식품 제조 시에 통상적으로 첨가되는 성분을 포함하며, 예를 들어, 단백질, 탄수화물, 지방, 영양소, 조미제 및 향미제를 포함한다. 상술한 탄수화물의 예는 모노사카라이드, 예를 들어, 포도당, 과당 등; 디사카라이드, 예를 들어 말토스, 슈크로스, 올리고당 등; 및 폴리사카라이드, 예를 들어 덱스트린, 사이클로덱스트린 등과 같은 통상적인 당 및 자일리톨, 소르비톨, 에리트리톨 등의 당알콜이다. 향미제로서 천연 향미제 [타우마틴, 스테비아 추출물 (예를 들어 레바우디오시드 A, 글리시르히진 등]) 및 합성 향미제(사카린, 아스파르탐 등)를 사용할 수 있다. 예컨대, 본 발명의 식품 조성물이 드링크제로 제조되는 경우에는 본 발명의 시계꽃 추출물 이외에 구연산, 액상과당, 설탕, 포도당, 초산, 사과산, 과즙, 두충 추출액, 대추 추출액, 감초 추출액 등을 추가로 포함시킬 수 있다.The composition of the present invention can be provided as a food composition. When a composition for preventing, ameliorating or treating sleep disorder comprising the clock flower extract of the present invention as an active ingredient is prepared from a food composition, not only clock flower extract as an active ingredient but also ingredients normally added in food production And includes, for example, proteins, carbohydrates, fats, nutrients, flavoring agents, and flavoring agents. Examples of the above-mentioned carbohydrates are monosaccharides such as glucose, fructose, and the like; Disaccharides such as maltose, sucrose, oligosaccharides and the like; And polysaccharides such as dextrin, cyclodextrin and the like, and sugar alcohols such as xylitol, sorbitol and erythritol. Natural flavorings such as tau martin and stevia extract (e.g., rebaudioside A and glycyrrhizin) and synthetic flavorings (saccharine, aspartame, etc.) can be used as flavorings. For example, when the food composition of the present invention is prepared as a drink, it may further contain citric acid, liquid fructose, sugar, glucose, acetic acid, malic acid, juice, mulberry extract, jujube extract, licorice extract, .
본 발명의 시계꽃 추출물을 유효성분으로 포함하는 수면장애의 예방, 개선 또는 치료용 조성물은 건강기능성 식품 조성물로 제조될 수 있다. 본 발명의 조성물이 건강기능성 식품 조성물로 제조되는 경우, 식품 제조 시 통상적으로 첨가되는 성분을 포함하며, 예를 들어, 단백질, 탄수화물, 지방, 영양소 및 조미제를 포함한다. 예컨대, 드링크제로 제조되는 경우에는 유효성분으로서 시계꽃 추출물 이외에 향미제 또는 천연 탄수화물을 추가 성분으로 포함시킬 수 있다. 예를 들어, 천연 탄수화물은 모노사카라이드(예컨대, 글루코오스, 프럭토오스 등); 디사카라이드(예컨대, 말토스, 수크로오스 등); 올리고당; 폴리사카라이드(예컨대, 덱스트린, 시클로덱스트린 등); 및 당알코올(예컨대, 자일리톨, 소르비톨, 에리쓰리톨 등)을 포함한다. 향미제로서 천연 향미제(예컨대, 타우마린, 스테비아 추출물 등) 및 합성 향미제(예컨대, 사카린, 아스파르탐 등)을 이용할 수 있다.The composition for preventing, ameliorating or treating sleep disorder comprising the clock flower extract of the present invention as an active ingredient may be prepared from a health functional food composition. When the composition of the present invention is prepared with a health functional food composition, it includes components that are conventionally added in the manufacture of foods, for example, proteins, carbohydrates, fats, nutrients, and seasonings. For example, in the case of being made with a drink, a flavoring agent or a natural carbohydrate may be added as an additional ingredient in addition to the clock flower extract as an active ingredient. For example, natural carbohydrates include monosaccharides (e.g., glucose, fructose, etc.); Disaccharides (e.g., maltose, sucrose, etc.); oligosaccharide; Polysaccharides (e.g., dextrin, cyclodextrin and the like); And sugar alcohols (e.g., xylitol, sorbitol, erythritol, etc.). Natural flavoring agents (e.g., tau marin, stevia extract, etc.) and synthetic flavoring agents (e.g., saccharin, aspartame, etc.) may be used as flavorings.
이하, 실시예를 통하여 본 발명을 더욱 상세히 설명하고자 한다. 이들 실시예는 오로지 본 발명을 보다 구체적으로 설명하기 위한 것으로, 본 발명의 요지에 따라 본 발명의 범위가 이들 실시예에 의해 제한되지 않는다는 것은 당업계에서 통상의 지식을 가진 자에 있어서 자명할 것이다.Hereinafter, the present invention will be described in more detail with reference to Examples. It is to be understood by those skilled in the art that these embodiments are only for describing the present invention in more detail and that the scope of the present invention is not limited by these embodiments in accordance with the gist of the present invention .
[실시예][Example]
실시예 1. 시계꽃으로부터 유효분획 및 유효성분 분리Example 1 Effective Fractionation and Effective Component Separation from Clock Flower
1.1. 추출물의 제조1.1. Preparation of extract
시계꽃(Passiflora caerulea)은 구입한 것을 사용하였고, 물 또는 알콜을 첨가하여 시계꽃 물 또는 알콜 추출물을 제조하였다. 상기 물 또는 알콜 추출물을 하기 실험에서 사용하였다. Passiflora caerulea was purchased and water or alcohol was added to make watch flower water or alcoholic extract. The water or alcohol extract was used in the following experiment.
실시예 2. 시계꽃 추출물의 뇌신경세포에 미치는 영향 확인Example 2. Confirmation of Effect of Clock Flower Extract on Cranial Cells
시계꽃 추출물의 진정 및 수면 유도 효과는 뇌신경에서 작용한다는 점에 착안하여, 뇌신경세포의 일종인 C6 glioma cell을 사용하여 효능 평가를 진행하였고, 덧붙여 시계꽃 추출물의 항산화 효과를 함께 평가하였다.The efficacy was evaluated using C6 glioma cell, a type of neuronal cell, and the antioxidant effect of the clock flower extract was evaluated together with the fact that the sedative and sleeping inducing effect of the clock flower extract acted in the cranial nerve.
그 결과, 도 1에 나타낸 것과 같이, 시계꽃 추출물은 고농도가 아닌 적정 농도에서 C6 glioma cell의 viability를 손상시키지 않는 것이 확인되었고(도 1A 및 1C), 60ug/ml의 농도로 처리했을 때 항산화 효능을 증가시키는 것이 확인되었다(도 1B).As a result, as shown in Fig. 1, it was confirmed that the clock flower extract did not impair viability of the C6 glioma cell at a proper concentration, not at a high concentration (Figs. 1A and 1C) (Fig. 1B).
실시예 3. 시계꽃 추출물의 c-fos 발현 증가 효과 확인Example 3. Confirmation of Increase of c-fos Expression Effect of Clock Flower Extract
뇌조직에서의 C-fos 단백질의 증가는, 발현 증가가 일어난 해당 신경세포에 자극이 증가했음을 의미하는 것으로, 본 실시예 3에서는 시계꽃 추출물의 경구투여 후 뇌조직에서 C-fos 단백질의 발현이 증가하는지를 확인하고자 하였다.The increase in C-fos protein in the brain tissue means that the stimulation is increased in the corresponding neuron where the expression is increased. In Example 3, the expression of C-fos protein in the brain tissue after oral administration of the clock flower extract .
뇌조직에서의 c-fos 단백질 발현이 증가된다는 것은 시계꽃 물질에 의해 영향을 받는다는 것을 유추할 수 있는 것으로, 뇌조직에서 외부 자극에 의한 C-fos 단백질의 발현은 15분 이내에 나타나는 것으로 알려져 있다.It is known that the increase of c-fos protein expression in brain tissue is influenced by the clock flower material. It is known that the expression of C-fos protein by external stimulation in brain tissue appears within 15 minutes.
3.1. 유두체에서의 c-fos 단백질 발현 증가 확인3.1. Increased expression of c-fos protein in papillary bodies
포유류의 뇌에서 유두체(mammillary body)는 수면과 관련이 있는 조직으로, 한 선행연구에서는, 불면증 환자의 경우 mammillary body의 수축이 일어난다고 보고한 바 있다.In the mammalian brain, the mammillary body is a tissue associated with sleep. In a previous study, it has been reported that shrinkage of the mammillary body occurs in patients with insomnia.
이에 고농도(500mg/ml)의 시계꽃 추출물(PF)을 마우스에 경구투여하고 30분 후, 마우스 뇌조직을 적출하여 C-fos antibody를 사용한 immunohistochemistry를 진행하였다.Then, 30 minutes after oral administration of high-concentration (500 mg / ml) clock flower extract (PF) to mice, mouse brain tissue was extracted and subjected to immunohistochemistry using C-fos antibody.
시상하부 조직의 mammillary body에서 C-fos 단백질이 매우 증가하였음을 확인하였다. 이는 시계꽃 추출물이 시상하부에 작용하며, 특히 수면작용과 관련이 있는 mammillary body의 기능에 영향을 미침을 의미하는 것이다.C-fos protein was significantly increased in the mammillary body of the hypothalamus. This implies that the clock flower extract acts on the hypothalamus, particularly the function of the mammillary body, which is associated with sleeping action.
그 결과, 도 2에 나타낸 것과 같이, 시계꽃 추출물의 경구투여가 마우스 시상하부의 mammillary body 조직에 영향을 미쳐, c-fos 단백질의 발현을 증가시킨다는 것을 확인하였다.As a result, as shown in Fig. 2, it was confirmed that the oral administration of the clock flower extract affects the mammillary body tissue of the hypothalamus of the mouse, thereby increasing the expression of c-fos protein.
3.2. 해마에서의 c-fos 단백질 발현 증가 확인3.2. Increased expression of c-fos protein in hippocampus
본 발명자들은 이전의 실험을 통해 뇌조직의 immunohistochemistry 염색을 통해 시계꽃 추출물의 단기투여는 DBA/2 mouse의 해마에서 신경재생을 촉진한다는 결과를 얻은 바 있으며, 이에 본 실시예 3.2에서는 시계꽃 추출물이 해마와 시상하부에 미치는 효과를 western blot을 활용하여 확인하였다.The present inventors have previously found that short-term administration of clock flower extract promotes nerve regeneration in the hippocampus of DBA / 2 mouse through immunohistochemistry of brain tissues. Thus, in Example 3.2, The effects on the hippocampus and hypothalamus were confirmed using western blot.
상기에서 기재한 것과 같이 C-fos 단백질의 증가는 해당 신경세포에 최근 전기적 신호가 지속적으로 전달되었음을 간접적으로 나타내는 지표로 활용되는 것으로, 도 3에 나타낸 것과 같이 시계꽃 추출물을 단기투여한 결과, 랫드의 해마에서 C-fos의 단백질이 증가한 것이 확인되어, 시계꽃 추출물이 해마조직의 신경세포에 영향을 주었다는 것을 알 수 있었다.As described above, the increase of the C-fos protein is indirectly used as an indicator indirectly indicating that the electrical signal is continuously transmitted to the nerve cell. As shown in Fig. 3, when the clock flower extract is administered for a short time, Of the C-fos protein increased in the hippocampus of the hippocampus, indicating that the clock flower extract influenced the nerve cells of the hippocampal tissue.
실시예 4. 시계꽃 추출물의 DCX 단백질 발현 증가 효과 확인Example 4. Confirmation of Increase of DCX Protein Expression of Clock Flower Extract
뇌조직에서의 Doublecortin(DCX) 단백질은, 신경이동 단백질의 일종으로 뇌 조직에서 신경재생의 지표로 활용된다.Doublecortin (DCX) protein in brain tissue is a type of neuronal migration protein that is used as an indicator of nerve regeneration in brain tissue.
이에 본 실시예 4에서는 시계꽃 추출물의 경구투여 후 해마 조직에서 DCX 단백질의 발현이 증가하는지를 확인하고자 하였다.Thus, in Example 4, the expression of DCX protein in hippocampal tissues after oral administration of clock flower extract was increased.
그 결과, 도 4에 나타낸 것과 같이, DCX의 발현이 시계꽃 추출물을 투여하지 않은 대조군에 비하여 더 증가되어 있다는 것을 확인하였다. 즉 본 발명의 시계꽃 추출물에는 수면장애를 개선하는 효과가 있다는 것을 알 수 있다.As a result, as shown in Fig. 4, it was confirmed that the expression of DCX was further increased as compared with the control group in which the clock flower extract was not administered. That is, the clock flower extract of the present invention has an effect of improving the sleeping disorder.
실시예 5. 시계꽃 추출물의 물 미로 실험에 의한 수면장애 개선 효과 확인Example 5 Confirmation of Improvement of Sleep Disorder by Water Maze Experiment of Clock Flower Extract
시계꽃 추출물이 수면을 유도하는 정확한 적정 농도를 설정하기 위해, 다양한 범위에서 농도를 변경해가며 투여해볼 필요가 있는 것으로 판단되어, 본 실시예 5에서는 DBA/2 mouse에 고농도 (500mg/kg)의 농도를 2주간 투여하였다.It is considered that it is necessary to change the concentration of the clock flower extract in various ranges in order to set the correct optimum concentration to induce the sleep. In Example 5, the DBA / 2 mouse was administered with a high concentration (500 mg / kg) For 2 weeks.
DBA/2 mouse는 수면장애를 가지고 있는 마우스 타입으로서, 본 발명자들의 선행 연구에서 저농도 (10mg/kg) 시계꽃 추출물이 DBA/2 mouse 해마의 신경재생 촉진효과를 보이는 결과를 immunohistochemistry 검사를 통해 확인한 바 있다. 이는 시계꽃 추출물이 DBA/2 마우스의 수면장애를 개선함으로써 나타난 결과라고 사료되었으므로, 따라서 동물실험 종료 직전에 물미로 실험(water maze test)을 실시하여, DBA/2 마우스의 해마신경재생 촉진효과가 행동학적 결과로 나타나는지 확인하였다.DBA / 2 mouse is a mouse type having a sleeping disorder. In a previous study conducted by the present inventors, immunohistochemistry test was performed to confirm that the low concentration (10 mg / kg) clock flower extract exhibits nerve regeneration effect of DBA / 2 mouse hippocampus have. This suggests that the clock flower extract is a result of the improvement of sleep disturbance in DBA / 2 mice. Therefore, water maze test was performed immediately before the end of the animal experiment to evaluate the effect of promoting hippocampal regeneration in DBA / And it was confirmed that it appeared as a behavioral result.
기존문헌에 기재된 물미로 실험 방법을 응용하여 하기와 같은 실험을 하였다. (Morris R. Developments of a water-maze procedure for studying spatial learning in the rat. J Neurosci. 11 : pp. 47-60, 1984. Han CK et el., SK-PC-B70M from Pulsatilla koreana improves scopolamine-induced impairments of memory consolidation and spatial working memory. Brain Res. 12 : pp.254-259, 2007)The following experiment was carried out by applying the experimental method to the bitterness described in the existing literature. SK-PC-B70M from Pulsatilla koreana improves scopolamine-induced < RTI ID = 0.0 > impairments of memory consolidation and spatial working memory. Brain Res. 12: pp. 254-259, 2007)
물미로 실험(Morris water-maze test)은 알파-피넨(α-pinene)이 실험동물의 공간지각능력 및 단기, 장기 기억력의 회복(short and long-term memory recovery)에 도움을 주는지 알아보기 위한 실험이다. 실험장비는 원형의 수조(stainless steel, 지름 120 cm, 높이 45 cm)와 도피대(platform, 지름 10cm, 높이 30 cm)로 이루어진다. 수조의 물(온도 22± 2℃) 높이는 플랫폼 위 2 cm까지로 마우스가 도피대에 앉으면 몸이 물 밖으로 나올 수 있도록 하였다. 물미로 실험은 실험동물이 수조 주변의 표지물을 이용하여 도피대를 찾아가기 때문에 주변의 환경 변화가 없도록 표지물을 실험기간 동안 일정하게 유지 하였다. 실험동물이 도피대를 찾아가 20초 이상 머무르면 찾아갈 때까지 걸린 시간을 탈출잠복기(escape latency)로 하였으며, 이를 하루 3회 실시하여 나온 평균값을 평균 탈출잠복기(mean escape latency)로 하였다. 탈출잠복기는 수조 위 천정에 카메라를 설치하여 컴퓨터 프로그램(Ethovision 3.1, Noduls, 네덜란드)을 통해 관찰하여 기록하였다. 실험은 5일 동안 매일 3회 실시하였으며, 이때 실험동물을 수조에 넣는 위치를 매회 순차적으로 달리하여 우연에 의해 도피대를 찾아가는 가능성을 최소화 하였다. 만약, 실험동물이 120초 내에 도피대를 찾지 못하면 탈출 잠복기를 120초로 하였으며, 실험동물이 도피대에 앉으면 20초간 두어 주변의 단서를 다시 기억할 수 있도록 하였다. The Morris water-maze test was conducted to investigate whether alpha-pinene helps the spatial perception of experimental animals and the short- and long-term memory recovery to be. Experimental equipment consists of a round steel tank (120 cm in diameter, 45 cm in height) and a platform (10 cm in diameter, 30 cm in height). The height of the water in the water tank (temperature 22 ± 2 ° C) was up to 2 cm above the platform so that when the mouse sat on the escape platform, the body could come out of the water. In the experiment with water, the test animals were kept at the same level during the experiment period so that the environment was not changed because the animals were looking for the escape pods using the markers around the water tanks. The time taken for the animals to visit when they visited the escape pod for more than 20 seconds was defined as the escape latency, and the mean value obtained by performing this three times a day was the mean escape latency. The incubation latency was recorded by observing the computer program (Ethovision 3.1, Noduls, The Netherlands) by installing a camera on the ceiling above the tank. The experiment was carried out three times daily for 5 days, and the possibility of visiting the esophagus by chance was minimized by sequentially changing the position of putting the experimental animals in the water tank every time. If the experimental animal can not find the esophagus within 120 seconds, the escape latency is set to 120 seconds. When the animal is sitting on the esophagus, it is left for 20 seconds to remind the surrounding clues.
그 결과, 도 5에 나타낸 것과 같이, 시계꽃 추출물을 투여한 그룹의 마우스들은, 대조군보다 water maze에서 부표를 찾아가는데 소요된 시간이 훨씬 빠르게 감소한다는 것을 확인하였다. 이와 같이, 시계꽃 추출물은 신경재생을 촉진하는 효과를 보이는 것이며, 상기와 같은 결과로부터 본 발명의 시계꽃 추출물에 의해 수면장애가 개선되리란 것을 예상할 수 있었다.As a result, as shown in Fig. 5, it was confirmed that the mice of the group to which the clock flower extract was administered showed a much faster decrease in the time taken to visit the buoys in the water maze than in the control group. As described above, the clock flower extract has an effect of promoting nerve regeneration. From the above results, it can be expected that the clock flower extract of the present invention can improve the sleep disorder.
이상으로 본 발명의 특정한 부분을 상세히 기술하였는바, 당업계의 통상의 지식을 가진 자에게 있어서 이러한 구체적인 기술은 단지 바람직한 구현예일 뿐이며, 이에 본 발명의 범위가 제한되는 것이 아닌 점은 명백하다. 따라서 본 발명의 실질적인 범위는 첨부된 청구항과 그의 등가물에 의하여 정의된다고 할 것이다.While the present invention has been particularly shown and described with reference to exemplary embodiments thereof, it is to be understood that the same is by way of illustration and example only and is not to be construed as limiting the scope of the present invention. It is therefore intended that the scope of the invention be defined by the claims appended hereto and their equivalents.
Claims (10)
A pharmaceutical composition for preventing, ameliorating, or treating a sleep disorder, comprising an extract of Passiflora caerulea as an active ingredient.
상기 추출물은 물, 에탄올, 디클로로메탄, 에틸아세테이트, 및 부탄올로 이루어지는 군으로부터 선택되는 1종 이상의 용매로 추출된 것을 특징으로 하는, 수면장애의 예방, 개선, 또는 치료용 약학적 조성물.
The method according to claim 1,
Wherein the extract is extracted with at least one solvent selected from the group consisting of water, ethanol, dichloromethane, ethyl acetate, and butanol.
상기 시계꽃 추출물은 시계꽃의 잎 또는 열매 추출물인 것을 특징으로 하는, 수면장애의 예방, 개선, 또는 치료용 약학적 조성물.
The method according to claim 1,
The pharmaceutical composition for preventing, ameliorating, or treating sleep disorder, wherein the clock flower extract is a leaf or fruit extract of a clock flower.
상기 추출물은 해마 조직에서 씨포스 및 더블코르틴 단백질의 발현을 증가시키는 것을 특징으로 하는, 수면장애의 예방, 개선, 또는 치료용 약학적 조성물.
The method according to claim 1,
The pharmaceutical composition for preventing, ameliorating, or treating sleep disorders, wherein the extract increases the expression of the cortex and double-core protein in hippocampal tissue.
상기 추출물은 시상하부의 유두체 조직에서 씨포스 단백질의 발현을 증가시키는 것을 특징으로 하는, 수면장애의 예방, 개선, 또는 치료용 약학적 조성물.
The method according to claim 1,
A pharmaceutical composition for preventing, ameliorating, or treating a sleep disorder, wherein the extract increases the expression of the c-spos protein in the hypothalamic papillary body tissue.
A health functional food composition for improving sleeping disorder, comprising Passiflora caerulea extract as an active ingredient.
상기 추출물은 물, 에탄올, 디클로로메탄, 에틸아세테이트, 및 부탄올로 이루어지는 군으로부터 선택되는 1종 이상의 용매로 추출된 것을 특징으로 하는, 수면장애 개선용 건강기능성 식품 조성물.
The method according to claim 6,
Wherein the extract is extracted with at least one solvent selected from the group consisting of water, ethanol, dichloromethane, ethyl acetate, and butanol.
상기 시계꽃 추출물은 시계꽃의 잎 또는 열매 추출물인 것을 특징으로 하는, 수면장애 개선용 건강기능성 식품 조성물.
The method according to claim 6,
Wherein the clock flower extract is a leaf or fruit extract of a clock flower.
상기 추출물은 해마 조직에서 씨포스 및 더블코르틴 단백질의 발현을 증가시키는 것을 특징으로 하는, 수면장애 개선용 건강기능성 식품 조성물.
The method according to claim 6,
Wherein said extract enhances the expression of the cortex and double core protein in hippocampal tissue.
상기 추출물은 시상하부의 유두체 조직에서 씨포스 단백질의 발현을 증가시키는 것을 특징으로 하는, 수면장애 개선용 건강기능성 식품 조성물.
The method according to claim 6,
Wherein said extract increases the expression of c-spos protein in the hypothalamic tissue of the hypothalamus.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020170160414A KR20190061737A (en) | 2017-11-28 | 2017-11-28 | Composition for Preventing, Improving or Treating Sleep Disorder Comprising Passiflora caerulea extract as an Active Ingredients |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020170160414A KR20190061737A (en) | 2017-11-28 | 2017-11-28 | Composition for Preventing, Improving or Treating Sleep Disorder Comprising Passiflora caerulea extract as an Active Ingredients |
Publications (1)
Publication Number | Publication Date |
---|---|
KR20190061737A true KR20190061737A (en) | 2019-06-05 |
Family
ID=66845313
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020170160414A KR20190061737A (en) | 2017-11-28 | 2017-11-28 | Composition for Preventing, Improving or Treating Sleep Disorder Comprising Passiflora caerulea extract as an Active Ingredients |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR20190061737A (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20210003970A (en) | 2019-07-02 | 2021-01-13 | 동의대학교 산학협력단 | Composition for inducing sleep including pelargonium graveolens oil |
-
2017
- 2017-11-28 KR KR1020170160414A patent/KR20190061737A/en unknown
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20210003970A (en) | 2019-07-02 | 2021-01-13 | 동의대학교 산학협력단 | Composition for inducing sleep including pelargonium graveolens oil |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2716296B1 (en) | Novel usage of rice bran, or rice hull extract as histamine receptor antagonist | |
KR102433207B1 (en) | Novel use of maydis stigma extract for preventing or treating sleep disorders | |
Wani et al. | Phytochemical screening and aphrodisiac property of Tinospora cordifolia | |
JP6898905B2 (en) | Composition for prevention, treatment and improvement of dysuria containing Indian pepper extract | |
US20080194499A1 (en) | Composition for selective serotonin reuptake inhibition and process thereof | |
RU2668135C1 (en) | Pharmaceutical composition for the treatment and prevention of degenerative neurological disorders which comprises, as an active ingredient, a mixed root extract of the tree peony root, the root of dahuric angelica and the root of thorowax or its fraction | |
EP2644198B1 (en) | Antianxiety and sleep disorder improving use of albiflorin | |
JP2008521839A (en) | Preparation method of large leaf (Kano) koji extract, extract and its application | |
KR20190061737A (en) | Composition for Preventing, Improving or Treating Sleep Disorder Comprising Passiflora caerulea extract as an Active Ingredients | |
KR20120132653A (en) | Novel use of rice bran extract or rice bran powder for improving, preventing or treating sleep disorders, anxiety, or depression | |
EP3235502B1 (en) | Composition containing poria cocos bark extract for preventing, improving or treating neurodegenerative disorders | |
EP2608798B1 (en) | Plant extracts made of sideritis and use thereof to boost cognitive performance | |
KR101263451B1 (en) | Composition for preventing and treating of neuropathic pain containing ginsenoside Rb1 and Rg3,Compound K,or saponin extract from Panax ginseng as an effective ingredient | |
KR20210047414A (en) | A composition for the prevention, improvement or treatment of sleep disorders containing Curcuma longa extract | |
KR101300775B1 (en) | Composition for preventing and treating of neuropathic pain containing ginsenoside Rb1 and Rg3,Compound K,or saponin extract from Panax ginseng as an effective ingredient | |
KR101316095B1 (en) | Composition for preventing and treating of neuropathic pain containing ginsenoside Rb1 and Rg3,Compound K,or saponin extract from Panax ginseng as an effective ingredient | |
CN110812450A (en) | Application of dendrobium nobile total alkaloids in preparation of intracerebral insulin signal regulator | |
KR101929353B1 (en) | Composition comprising the extract of Sprouts Valerian fauriei having anti-depressant activity | |
KR20190102846A (en) | Novel use of xanthii fructus extract for preventing or treating sleep disorders | |
KR20150110949A (en) | A composition for preventing, treating and improving of voiding disorder comprising herbal extract | |
KR102493641B1 (en) | Composition for preventing or treating sleep disorders comprising Massa Medicata Fermentata extracts | |
KR20130112012A (en) | Compositions for preventing or treating depression comprising morus alba radicis extracts as active ingredients | |
KR102152182B1 (en) | A composition for the prevention or treatment of depression, stress or memory malfunctions containing Geum aleppicum extract | |
KR101457442B1 (en) | A composition for histamine receptor antagonist comprising gamma-oryzanol as an effective ingredient | |
KR102262759B1 (en) | A composition for reducing side effects of GABAA receptor agonist, comprising phloroglucinol as an effective ingredient |